Barclays PLC Buys 106,018 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Barclays PLC lifted its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10,601,800.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 106,019 shares of the company's stock after purchasing an additional 106,018 shares during the quarter. Barclays PLC owned approximately 0.16% of Corvus Pharmaceuticals worth $567,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Raymond James Financial Inc. bought a new stake in shares of Corvus Pharmaceuticals during the 4th quarter worth $583,000. Renaissance Technologies LLC lifted its position in Corvus Pharmaceuticals by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 390,688 shares of the company's stock worth $2,090,000 after acquiring an additional 4,100 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in Corvus Pharmaceuticals during the fourth quarter valued at about $72,000. Geode Capital Management LLC grew its position in shares of Corvus Pharmaceuticals by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 566,863 shares of the company's stock valued at $3,034,000 after purchasing an additional 3,854 shares during the last quarter. Finally, PKS Advisory Services LLC bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth about $56,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. Oppenheimer reaffirmed an "outperform" rating and set a $17.00 target price (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.33.

Corvus Pharmaceuticals Stock Down 8.6%

Corvus Pharmaceuticals stock traded down $0.38 during trading hours on Monday, hitting $4.05. The stock had a trading volume of 2,514,640 shares, compared to its average volume of 708,923. The company has a 50-day moving average of $3.62 and a two-hundred day moving average of $5.46. Corvus Pharmaceuticals, Inc. has a fifty-two week low of $1.75 and a fifty-two week high of $10.00. The company has a market cap of $276.08 million, a PE ratio of -4.35 and a beta of 0.67.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). As a group, analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.